Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
17 déc. 2018 07h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30% This marks Company’s second Phase 3 program in rare...
PAVmed Provides Business Update
17 oct. 2018 07h30 HE
|
PAVmed Inc.
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on...
Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union
18 sept. 2018 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as...
RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc.
10 sept. 2018 15h30 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- September 10, 2018 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on...
U.S. FDA Approves Terumo BCT’s Sodium Citrate 4% w/v Anticoagulant Solution Amid Shortage
18 juil. 2018 10h04 HE
|
Terumo BCT
Lakewood, Colorado, USA, July 18, 2018 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) recently approved Terumo BCT’s Sodium Citrate 4% w/v Anticoagulant Solution USP, indicated for...
Epilepsy Foundation Testifies Before FDA Advisory Committee in Support of Potential First-Ever Cannabidiol Drug to Treat Dravet Syndrome
19 avr. 2018 12h07 HE
|
Epilepsy Foundation
WASHINGTON, April 19, 2018 (GLOBE NEWSWIRE) -- Philip Gattone, president and CEO of the Epilepsy Foundation, along with other epilepsy advocates, today testified at the U.S. Food & Drug...
Advanced Biomedical Technologies Inc. Announces Chinese CFDA Approval of Polymer Fixation Screws
19 avr. 2018 11h50 HE
|
Advanced Biomedical Technologies Inc
SHENZHEN, CHINA and NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Advanced Biomedical Technologies Inc. (OTCQB:ABMT), a developer and manufacturer of orthopaedic internal fixation devices, announced...
Amedica announces FDA Clearance of the Valeo C+CSC with Lumen Interbody Fusion Device
06 mars 2018 09h00 HE
|
Amedica Corporation
SALT LAKE CITY, UT, March 06, 2018 (GLOBE NEWSWIRE) -- Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company that develops and commercializes silicon nitride as a platform for...
FDA to Send Contractor to Inspect Vape Shops
15 févr. 2018 12h38 HE
|
US Federal Contractor Registration
Rockville, MD, Feb. 15, 2018 (GLOBE NEWSWIRE) -- The Food and Drug Administration (FDA) will be sending a contractor to inspect entities engaged in retail activities where tobacco regulated products...
AXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable Product to Marinol; Green Light from FDA for IND Submission
12 déc. 2017 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Dec. 12, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), a world leader in cannabinoid research and development, announced today that it has successfully completed a...